Philips V60 Plus enables clinicians to enhance patient outcomes with less invasive respiratory care therapies.Credit: Koninklijke Philips N.V

Dutch multinational technology company Royal Philips has received CE mark approval for its Philips V60 Plus Ventilator.

This solution builds on its noninvasive ventilation (NIV) gold standard platform, integrating NIV and high flow therapy (HFT) in a single device.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“V60 Plus is designed for early intervention in respiratory failure and enables clinicians to improve patient outcomes with less invasive respiratory care therapies.”

The device helps clinicians to quickly adjust therapies according to the condition of patients without switching devices.

V60 Plus is designed for early intervention in respiratory failure and enables clinicians to improve patient outcomes with less invasive respiratory care therapies.

Although early implementation with NIV is associated with less endotracheal intubation, sometimes clinicians face challenges when taking patients off this therapy.

Philips Hospital Respiratory Care business leader Jim Alwan said: “When treating respiratory patients in Intensive and Emergency Care settings, it’s critical for clinicians to be able to wean efficiently or to quickly escalate care depending on their patient’s condition and specific needs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This often means complex workflows and alternating devices in time-sensitive situations. We are excited to offer a comprehensive noninvasive solution that enables quick therapy and interface transitions, so clinicians can focus on providing for their patients while spending less time setting up equipment.”

Stockholm-based St. Goran Hospital NIV programme leader Peter Lindberg said: “We are delighted with the high flow function of the V60 Plus. It saves us a lot of time and space as we can use the same equipment for both NIV and high flow.

“When you need to wean patients from NIV to HFT, it is very simple with the one device. Additionally, the cannula is high quality, easy to adjust, soft against the patient’s skin and V60 flow is much quieter than our standalone high flow system.”

Following the CE mark approval, V60 Plus is available for sale in Europe. The firm has submitted a 510k application to the US Food and Drug Administration (FDA) for the device.